The Goldman Sachs Group, Inc. (NYSE:GS) [Trend Analysis] plunged reacts as active mover, shares a decrease -0.13% to traded at $171.43 and the percentage gap among open changing to regular change was -0.48%. Goldman Sachs Group Inc.’s co-head of global equities trading and execution services, Peter Selman, is retiring and will be replaced by partner Philip Berlinski, the bank stated in a memo on Thursday.
Brian Levine will remain as co-head of global equities trading, according to the memo, a copy of which was reviewed by Reuters. A Goldman spokeswoman confirmed the contents of the memo. Goldman competes fiercely with Morgan Stanley for the top rankings on Wall Street as a stock trading franchise. During the q2, Goldman generated equities income of $1.8 billion as compared with $2.1 billion for Morgan Stanley. The firm past twelve months price to sales ratio was 2.00 and price to cash ratio remained 0.49. As far as the returns are concern, the return on equity was recorded as 6.30% and return on investment was 1.10% while its return on asset stayed at 0.50%. The firm has total debt to equity ratio measured as 6.97.
bluebird bio, Inc. (NASDAQ:BLUE) [Trend Analysis] attempts to attain leading position in street, Shares price changes as it -3.56% to close at $55.46 with the total traded volume of 93448 shares. Bluebird Bio (BLUE) removed a important concern investors had about its gene therapy manufacturing process, sending shares higher Thursday.
The firm revealed the start of a new phase III study of its LentiGlobin gene therapy in patients with beta thalassemia, a rare blood disorder. Most importantly, Bluebird stated the new study incorporates changes to the way LentiGlobin is made, aimed at improving the number of corrected genes infused into patients and boosting efficacy.
The U.S. Food and Drug Administration is allowing Bluebird to treat beta thalassemia patients with the revamped LentiGlobin gene therapy without requiring the firm to start over with new preclinical data. This eliminates a lingering concern on the Street that Bluebird’s gene therapy studies would be importantly delayed by the manufacturing changes. The firm has institutional ownership of 98.10%, while insider ownership included 1.10%. Its price to sales ratio ended at 370.64. BLUE attains analyst recommendation of 1.80 with week performance of 16.56%.